Summary Pyrazinamide, the pyrazine analogue of nicotinamide, has been evaluated for its ability to modify the radiation response 
Overcoming the problem of radioresistant hypoxic cells has been a major focus of work in radiation biology over the last three decades (Barendson et al., 1966; Coleman, 1988; Henk et al., 1977; Hirst, 1986 ; Thomlinson & Gray, 1955) . Much of the research in this area has been centred on identifying chemical agents which can selectively increase the radiation response of these cells (Adams et al., 1976; Adams, 1984; Brown, 1989) . Many agents have been identified which can reduce the problem of radiobiologically hypoxic cells either through direct radiosensitisation (Adams et al., 1976; Brown 1989) or by improved oxygen delivery (Teicher & Rose, 1984; Hirst & Wood, 1989) . However, to date the success of such chemical intervention in improving clinical response to radiation treatment has been limited (Dische, 1989) . Progress in the search for more effective drugs can take two lines. One is to develop more efficient and/or less toxic derivatives of an already identified group of agents (Adams et al., 1979; Brown & Workman, 1980 (Johnsson et al., 1985; Horsman et al., 1986 Horsman et al., , 1987 Horsman et al., , 1988 . Screening a number of custom synthesised analogues of nicotinamide has not as yet identified any superior compounds (Horsman et al., 1986) . However, one compound certainly worthy of investigation, based on the fact that it is used clinically, is the pyrazine analogue of nicotinamide, pyrazinamide (Weinstein, 1975) . In the present study we have evaluated the radiosensitising effect of pyrazinamide in three murine tumours.
Materials and methods

Tumour systems
The three tumour systems used were the EMT6 grown in Balb/C mice, the Lewis lung carcinoma (LLC) grown in C57B1/6 mice and the squamous cell carcinoma SCCVII grown in C3H/He mice (purchased from Charles River, Quebec, Canada). Details of the derivation and maintenance of these lines have been described previously (Rockwell et al., 1972; Chaplin et al., 1983; Olive et al., 1985) . Solid tumours were produced by either intradermal (EMT6) or subcutaneous (LLC, SCCVII) implantation in 2-3 month old female mice. 
Irradiation procedure
The procedure was based on the technique described by Sheldon and Hill (1977) . Mice were restrained unanaesthetised in individual Perspex boxes from which a portion of lead shield had been cut to expose the posterior dorsum bearing the tumour to a horizontal X-ray beam. LLC and SCCVII tumours were irradiated using a 270 kVp X-ray machine (dose rate 3.1 Gy min ', HVL 1.7 mm Cu). EMT6 tumours were irradiated using a 250 kVp X-ray machine (dose rate 2.1 Gy min-', HVL 1.0 mm Cu).
For crypt cell survival studies, irradiation was given to the whole body at a dose rate of 1.5 Gy min-' using a 270 kVp X-ray machine (HVL 1.7 mm Cu).
Assessment of tumour response Tumour response was assayed by in vitro survival of tumour cells. For the EMT6 tumours survival was determined, as previously described (Horsman et al., 1984) (Courtenay, 1976 (Moore et al., 1976) . Briefly, a stirred suspension of CHO cells (2 x I05cells ml-') was incubated in medium with or without drug for I h at 37°C prior to irradiation, with nitrogen flow used to remove oxygen (for radiosensitisation). For toxicity assessment, a small aliquot of cells was added at zero time to pregassed (N2) medium at 37°C (final concentration again 2 x 105 cells ml-') with or without drug. In both cases, aliquots were removed after the given dose or incubation time, washed and plated for clonogenic ability.
Laser dopplerflowmetry Details of this technique are described in detail elsewhere (Shepherd et al., 1987; Trotter et al., 1989a 
Measurement of microregional perfusion changes
The use of sequential injections of Hoechst 33342 and carbocyanine -derivative DiOC7(3) to quantify changes in functional tumour vasculature has been described in detail previously (Trotter et al., 1989a,b,c Figure 1 . It can be seen that pyrazinamide enhances radiation induced cell killing when administered before radiation but has little or no effect when administered post-irradiation. The maximum effect is observed when pyrazinamide is administered 30-60 min prior to the commencement of radiation treatment. In Figure  2 the effect of administering pyrazinamide (0.5 mg g-'i.p.) 45 min prior to radiation on the survival response obtained with EMT6, LLC and SCCVII tumours is shown. Although in the absence of radiation pyrazinamide does not affect survival, it does increase tumour response in the presence of radiation in all three tumour lines investigated. Dose modification factors obtained are between 1.3 and 1.6. In order to ascertain if therapeutic gain could accrue from the use of pyrazinamide we have assessed its effect on the radiation response of mouse intestine using the crypt cell survival end point. The results shown in Figure 3 demonstrate that pyrazinamide does enhance radiation induced damage to crypt cells but to a lesser extent than seen with tumour. The radiation response curve is shifted down in a parallel fashion with a dose modification factor of between 1.0 and 1.2 over the radiation dose range studied.
To establish the mechanism responsible for the enhancement of tumour radiation response in vivo we have evaluated the radiosensitising and toxic effects of pyrazinamide on hypoxic cells in vitro. Figure 4 shows the radiation response of hypoxic CHO cells in vitro without drug or in the presence of either 10 mm misonidazole or 10 mM pyrazinamide. While misonidazole enhances radiation response of the cells (ER approx. 2.2), pyrazinamide has no observable effect. Figure 5 shows the hypoxic toxicity of either 10 mM misonidazole or 10 mM pyrazinamide over a 5 h incubation period. The results clearly show that over this time period misonidazole is cytotoxic to the hypoxic CHO cells while pyrazinamide has no effect. The absence of cytotoxicity towards hypoxic cells and lack of a marked effect of pyrazinamide on radiation response in vitro would suggest that the in vivo effect results either from a metabolite or from induced physiological changes in the animal. The results in Figure 6 show red blood cell (RBC) flow in SCCVII tumours as a function of time after pyrazinamide (0.5 mg g-' i.p.). A small increase in RBC flow occurs after drug administration. The maximum increase was 32% which was reached 40-45 min after drug administration. In addition to overall blood flow we have assessed the effect of pyrazinamide on the dynamic microregional heterogeneity of perfusion. tumour regions as well as overall. The values obtained (± standard deviation) were (1) saline controls: central 14.5 (± 4.5), peripheral 7.8 (± 2.2), overall 10.3 (± 2.9); (2) pyrazinamide pretreatment: central 4.4 (± 2.8), peripheral 2.6 (± 0.9), overall 3.2 (± 1.5); simultaneous stain injection: central 1.6 (± 0.6), peripheral 1.1 (± 0.6), overall 1.3 (± 0.6). Time (Minutes) Figure 1 The effect of pyrazinamide (0.5 mg g-i.p.) administered at various times before (-) or after (+) a fixed dose of X-rays.
Cell survival was assessed 18 h after radiation. Shaded areas represent the effect of X-rays alone ± standard deviation. X-ray dose for EMT6 was 20 Gy, for LLC was 15 Gy. 
Discussion
The results obtained show that pyrazinamide enhances the radiation response of three different murine tumour lines. Dose modification factors obtained for EMT6, LLC and SCCVII tumours are 1.6, 1.5 and 1.3 respectively. This enhancement of radiation effects seen in tumours is higher than the DMF of 1.0-1.2 obtained in mouse intestine, indicating the potential for therapeutic gain. Studies designed to indicate the mechanism of action of pyrazinamide suggest that changes in microregional blood flow may be involved. The radiation dose modification factors obtained for pyrazinamide in both tumours and intestine are comparable with these previously reported with nicotinamide (Horsman et al., 1986 (Horsman et al., , 1987 . The in vitro data show that unlike the electron affinic radiosensitiser misonidazole, pyrazinamide displays no radiosensitising or toxic effects on hypoxic cells in culture. These comparisons were carried out at equimolar doses of both pyrazinamide and misonidazole. These findings suggest that pyrazinamide effects seen in vivo do not result from a direct radiosensitising action or from hypoxic cell cytotoxic effects of the parent molecule. This indicates that other in vivo processes are operating. Pyrazinamide may be metabolised in vivo to a product(s) which possesses direct radiosensitising and/or toxic properties towards hypoxic cells. Another possibility is that pyrazinamide (or a primary metabolite) could modify physiological parameters within the tumour resulting in a reduction in the radiobiologically hypoxic fraction. One key parameter in determining the number of hypoxic cells present in the tumour is oxygen delivery. Recent studies with nicotinamide have shown that a contributing factor to the radiosensitisation seen with this compound is microregional changes in tumour blood flow (Horsman et al., 1989; Chaplin et al., 1990) ; therefore, we have sought to establish if similar effects occur after pyrazinamide administration. Laser doppler flowmetry studies in the SCCVII tumour indicate that pyrazinamide produces a small (32%) but significant (P <0.05) increase in blood flow in this tumour. However, this finding, although indicating that blood flow changes can occur after pyrazinamide, does not elucidate whether this reflects a small increase in flow in all tumour vessels, or a large increase in flow in a few vessels. This arises from the fact that although laser doppler flowmetry measures flow in a relative small volume (approx. 1 mm3) compared to other techniques, such a volume still contains many blood vessels. The significance of this limitation would be particularly important if radiobiological hypoxia can occur from transient fluctuations in microregional blood flow and thus oxygen delivery. Such hypoxia is known to occur in experimental tumour systems (Chaplin et al., 1986 Trotter et al., 1989b; Minchinton et al., 1990) . Indeed, in the SCCVII tumour at a size of 500mg, 8-10% of tumour vessels can open and close during a 20min period (Trotter, 1989b) . This latter study utilised a histological procedure which can provide a map of microregional blood flow (with resolution of single vessels) at two instances in time. The technique appears well suited to follow drug induced changes in functional vasculature (Trotter, 1989c; Zwi et al., 1989) . Using this technique with the SCCVII tumour, our present studies demonstrate that pyrazinamide has a marked effect on transient nonperfusion of vessels. Staining mismatch was reduced from 10.3% to 3.2% by pretreatment with pyrazinamide. This value is not significantly different from the background value obtained when the two fluorescent stains are injected simultaneously. These data provide evidence that at least part of the effect of pyrazinamide may be mediated by a reduction in 'acate' radiobiological hypoxia resulting from transient fluctuations in microregional perfusion. Similar results have been recently reported with nicotinamide .
The modification of tumour hypoxia may not afford a complete explanation for the results obtained. This could be inferred from two factors in the survival curves shown in Figure  2 . One is that survival levels at radiation doses of 15 Gy and above are higher than those expected from a totally aerobic population (Chaplin & Horsman, unpublished results) . Secondly, the terminal slopes of the in vivo survival curves from pyrazinamide pretreated animals do not become parallel to the X-ray only curves, as would be expected if a residual hypoxic fraction remained. These findings could imply that some radiosensitising action (via a metabolite) is superimposed on the physiological actions of pyrazinamide.
However, an alternative explanation which does not require any radiosensitising component to exist is that the remaining hypoxic cells after pyrazinamide pretreatment are diffusion limited 'chronically' hypoxic cells which possess a more sensitive radiation response than the acutely hypoxic cells (Franko & Sutherland, 1979) .
Overall, the in vivo and in vitro results obtained with pyrazinamide bear a marked similarity to those previously reported for nicotinamide, thus suggesting common mechanisms of action. The fact that pyrazinamide is already clinically used in the treatment of tuberculosis (Weinstein, 1975) and the results presented here strongly suggest further studies with pyrazinamide and related analogues as modifiers of tumour response to ionising radiation.
